Apogee Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Net Income	-274.62	-255.84	-182.15	-83.99
Depreciation & Amortization	1.62	1.42	0.19	-
Stock-Based Compensation	52.31	46.28	23.33	6.1
Other Adjustments	-2.87	-3.82	-10.55	-2.98
Changes in Accounts Payable	-1.21	0.15	-1.07	1.61
Changes in Accrued Expenses	0.96	-1.07	6.29	7.65
Changes in Other Operating Activities	-10.73	-14.55	-7.22	-3.16
Operating Cash Flow	-234.54	-227.45	-171.17	-74.76
Capital Expenditures	-0.83	-5.15	-1.15	-0.17
Purchases of Investments	-727.34	-642.3	-649.45	-303.74
Proceeds from Sale of Investments	500.27	467.87	350.14	30
Investing Cash Flow	-227.91	-179.57	-300.46	-273.91
Issuance of Common Stock	787.65	396.49	495.11	315.39
Net Common Stock Issued (Repurchased)	787.65	396.49	495.11	315.39
Financing Cash Flow	807.04	396.49	495.11	315.39
Net Cash Flow	344.59	-10.53	23.47	-33.28
Free Cash Flow	-235.37	-232.6	-172.33	-74.93
Free Cash Flow Per Share	-3.70	-3.83	-3.12	-3.00
Levered Free Cash Flow	-284.61	-275.05	-185.11	-78.05
Unlevered Free Cash Flow	-315.38	-304.49	-219.81	-87.07

Updated May 11, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q